High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults

Pediatric Blood and Cancer

Volumn 45, Issue 1, 2005, Pages 25-31

  Le Deley, Marie Cécile ^a   Vassal, Gilles ^b   Taïbi, Ahmed ^b   Shamsaldin, Akthar ^c   Leblanc, Thierry ^d   Hartmann, Olivier ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b IGR   (France)

^c INSERM   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

Child; Continuous etoposide; Etoposide; Schedule; Secondary leukemia; Therapy related leukemia

Indexed keywords

ALKYLATING AGENT; ETOPOSIDE;

ADOLESCENT; ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHILD; CHROMOSOME 11Q; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; FEMALE; HUMAN; LEUKEMIA; MALE; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; SOLID TUMOR;

ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; INCIDENCE; INFANT; LEUKEMIA; MALE; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PALLIATIVE CARE; SURVIVAL RATE;

EID: 20344374970     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20380     Document Type: Article

References (31)

1. Hainsworth JD, Johnson DH, Greco FA. Chronic etoposide schedules in the treatment of non-Hodgkin's lymphoma. Semin Oncol 1992;19:13-18.
2. Miller AA, Tolley EA, Niell HB, et al. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 1993;11:1179-1188.
3. Slevin ML, Joel SP. Prolonged oral etoposide in small cell lung cancer. Ann Oncol 1993;4:529-532.
4. Chamberlain MC, Grafe MR. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol 1995;13:2072-2076.
5. Chamberlain MC. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch Neurol 1997;54:554-558.
6. Chamberlain MC, Kormanik PA. Chronic oral VP-16 for recurrent medulloblastoma. Pediatr Neurol 1997;17:230-234.
7. Chamberlain MC. Recurrent intracranial ependymoma in children: Salvage therapy with oral etoposide. Pediatr Neurol 2001;24:117-121.
8. Davidson A, Gowing R, Lowis S, et al. Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG). Eur J Cancer 1997;33:1816-1822.
9. Philips MB, Flamant F, Sommelet-Olive D, et al. Pahe II study of rapid-schedule etoposide in paediatric soft tissue sarcomas. Eur J Cancer 1995;31:782-784.
10. Cappelli C, Hartmann O, Pein F. Efficacy of palliative oral etoposide (E) in metastatic neuroblastoma (NB) relapsing after high-dose chemotherapy (HDCT). Med Ped Oncol 1995;25:319.
11. Cooper MA, Einhorn LH. Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors. J Clin Oncol 1995;13:1167-1169.
12. Kushner BH, Kramer K, Cheung NK. Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol 1999;17:3221-3225.
13. Le Deley MC, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: A case-control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 2003;21:1074-1081.
14. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
15. Goto H, Shimazaki C, Tatsumi T, et al. Acute myelomonocytic leukemia after treatment with chronic oral etoposide: Are MLL and LTG9 genes targets for etoposide? Int J Hematol 1994;60:145-149.
16. Katato K, Flaherty L, Varterasian M. Secondary acute myelogenous leukemia following treatment with oral etoposide. Am J Hematol 1996;53:54-55.
17. Kikuta T, Shimazaki C, Hirai H, et al. Three cases of secondary acute myeloid leukemia after long-term treatment with oral etoposide. Rinsho Ketsueki 1996;37:1276-1282.
18. Ng A, Taylor GM, Eden OB. Secondary leukemia in a child with neuroblastoma while on oral etoposide: What is the cause? Pediatr Hematol Oncol 2000;17:273-279.
19. Rose PG, Blessing JA, Soper JT, et al. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: A gynecologic oncology group study. Gynecol Oncol 1998;70:267-271.
20. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1998;16:405-410.
21. Schiavetti A, Varrasso G, Maurizi P, et al. Ten-day schedule oral etoposide therapy in advanced childhood malignancies. J Pediatr Hematol Oncol 2000;22:119-124.
22. Schiavetti A, Varrasso G, Maurizi P, et al. Two secondary leukemias among 15 children given oral etoposide. Med Pediatr Oncol 2001;37:148-149.
23. Yagita M, Ieki Y, Onishi R, et al. Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer. Int J Oncol 1998;13:91-96.
24. Pui CH, Relling MV. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 2000;109:13-23.
25. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-1687.
26. Chen CL, Fuscoe JC, Liu Q, et al. Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J Natl Cancer Inst 1996;88:1840-1847.
27. Aydiner A, Koyuncu H, Tas F, et al. Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day. Int J Clin Pharmacol Res 2000;20:21-30.
28. Minami H, Ando Y, Sakai S, et al. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J Clin Oncol 1995;13:191-199.
29. Diallo I, Lamon A, Shamsaldin A, et al. Estimation of the radiation dose delivered to any point outside the target volume per patient treated with external beam radiotherapy. Radiother Oncol 1996;38:269-271.
30. Shamsaldin A, Grimaud E, Hardiman C, et al. Dose distribution throughout the body from radiotherapy for Hodgkin's disease in childhood. Radiother Oncol 1998;49:85-90.
31. Cristy M. Active bone marrow distribution as a function of age in humans. Phys Med Biol 1981;26:389-400.